Antibodies to S. aureus surface determinants

Patent metadata

Field	Value
Publication number	US-9879070-B2
Application number	US-201314440748-A
Country	US
Kind code	B2
Filing date	Nov 6, 2013
Priority date	Nov 6, 2012
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus ( S. aureus ) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.

First claim

What is claimed is:

1. An isolated antibody or antigen binding fragment thereof that specifically binds to the Staphylococcus aureus ( S. aureus ) ClfA surface determinant antigen,
wherein the isolated antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region VL [(VH)], each of which comprises three complementarity determining regions (CDR1, CDR2, and CDR3)
and wherein:
a. a VH CDR1 is identical to the amino acid sequence of SEQ ID NO: 133;
b. a VH CDR2 is identical to the amino acid sequence of SEQ ID NO: 134; and
c. a VH CDR3 is identical to the amino acid sequence of SEQ ID NO: 135; and
d. a VL CDR1 is identical to the amino acid sequence of SEQ ID NO: 137;
e. a VL CDR2 is identical to the amino acid sequence of SEQ ID NO: 138; and
f. a VL CDR3 is identical to the amino acid sequence of SEQ ID NO: 139.

2. An isolated antibody or antigen binding fragment thereof of claim 1 , wherein the VH amino acid sequence is 100% identical to the amino acid sequence of SEQ ID NO: 132 and the VL amino acid sequence is 100% identical to the amino acid sequence of SEQ ID NO: 136.

3. A composition comprising the isolated antibody or antigen binding fragment thereof of claim 1 , and a pharmaceutically acceptable excipient.

4. An isolated antibody or antigen binding fragment thereof that specifically binds to the Staphylococcus aureus ( S. aureus ) ClfA surface determinant antigen,
wherein the isolated antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region VL [(VH)], each of which comprises three complementarity determining regions (CDR1, CDR2, and CDR3)
and wherein:
a. a VH CDR1 is identical to the amino acid sequence of SEQ ID NO: 141;
b. a VH CDR2 is identical to the amino acid sequence of SEQ ID NO: 142; and
c. a VH CDR3 is identical to the amino acid sequence of SEQ ID NO: 143; and
d. a VL CDR1 is identical to the amino acid sequence of SEQ ID NO: 145;
e. a VL CDR2 is identical to the amino acid sequence of SEQ ID NO: 146; and
f. a VL CDR3 is identical to the amino acid sequence of SEQ ID NO: 147.

5. An isolated antibody or antigen binding fragment thereof of claim 4 , wherein the VH amino acid sequence is identical to the amino acid sequence of SEQ ID NO: 140 and the VL amino acid sequence is identical to the amino acid sequence of SEQ ID NO: 144.

6. A composition comprising the isolated antibody or antigen binding fragment thereof of claim 4 , and a pharmaceutically acceptable excipient.

Assignees

• Medimmune Llc

Inventors

• Sellman Brett
• Tkaczyk Christine
• Chowdhury Partha S
• Hua Lei
• Pavlik Peter
• Buonpane Rebecca
• Chang Chew-Shun

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title